230 related articles for article (PubMed ID: 1459169)
1. Supplementation with n-3 fatty acids reduces triglycerides but increases PAI-1 in non-insulin-dependent diabetes mellitus.
Boberg M; Pollare T; Siegbahn A; Vessby B
Eur J Clin Invest; 1992 Oct; 22(10):645-50. PubMed ID: 1459169
[TBL] [Abstract][Full Text] [Related]
2. A controlled study on the effects of n-3 fatty acids on lipid and glucose metabolism in non-insulin-dependent diabetic patients.
Annuzzi G; Rivellese A; Capaldo B; Di Marino L; Iovine C; Marotta G; Riccardi G
Atherosclerosis; 1991 Mar; 87(1):65-73. PubMed ID: 1872925
[TBL] [Abstract][Full Text] [Related]
3. Long-term effects of fish oil on insulin resistance and plasma lipoproteins in NIDDM patients with hypertriglyceridemia.
Rivellese AA; Maffettone A; Iovine C; Di Marino L; Annuzzi G; Mancini M; Riccardi G
Diabetes Care; 1996 Nov; 19(11):1207-13. PubMed ID: 8908381
[TBL] [Abstract][Full Text] [Related]
4. On the effects of dietary n-3 fatty acids (Maxepa) on plasma lipids and lipoproteins in patients with hyperlipidaemia.
Simons LA; Hickie JB; Balasubramaniam S
Atherosclerosis; 1985 Jan; 54(1):75-88. PubMed ID: 3888229
[TBL] [Abstract][Full Text] [Related]
5. Effects of fish oil supplements in NIDDM subjects. Controlled study.
Hendra TJ; Britton ME; Roper DR; Wagaine-Twabwe D; Jeremy JY; Dandona P; Haines AP; Yudkin JS
Diabetes Care; 1990 Aug; 13(8):821-9. PubMed ID: 2209315
[TBL] [Abstract][Full Text] [Related]
6. Dietary supplementation with n-3 fatty acids may impair glucose homeostasis in patients with non-insulin-dependent diabetes mellitus.
Vessby B; Boberg M
J Intern Med; 1990 Aug; 228(2):165-71. PubMed ID: 2394967
[TBL] [Abstract][Full Text] [Related]
7. Effects of Maxepa on serum lipids in hypercholesterolaemic subjects.
Dart AM; Riemersma RA; Oliver MF
Atherosclerosis; 1989 Dec; 80(2):119-24. PubMed ID: 2692571
[TBL] [Abstract][Full Text] [Related]
8. Dietary supplementation with highly purified eicosapentaenoic acid and docosahexaenoic acid does not influence PAI-1 activity.
Hansen J; Grimsgaard S; Nordoy A; Bonaa KH
Thromb Res; 2000 Apr; 98(2):123-32. PubMed ID: 10713313
[TBL] [Abstract][Full Text] [Related]
9. A comparison of the effects of n-3 fatty acids from linseed oil and fish oil in well-controlled type II diabetes.
McManus RM; Jumpson J; Finegood DT; Clandinin MT; Ryan EA
Diabetes Care; 1996 May; 19(5):463-7. PubMed ID: 8732710
[TBL] [Abstract][Full Text] [Related]
10. Reduction in plasminogen activator inhibitor-1 (PAI-1) with omega-3 polyunsaturated fatty acid (PUFA) intake.
Mehta J; Lawson D; Saldeen TJ
Am Heart J; 1988 Nov; 116(5 Pt 1):1201-6. PubMed ID: 3142242
[TBL] [Abstract][Full Text] [Related]
11. [The effect of n-3 fatty acid administration on selected indicators of cardiovascular disease risk in patients with type 2 diabetes mellitus].
Habán P; Simoncic R; Klvanová I; Ozdín L; Zideková E
Bratisl Lek Listy; 1998 Jan; 99(1):37-42. PubMed ID: 9588078
[TBL] [Abstract][Full Text] [Related]
12. Effects of fish oil supplementation on glucose and lipid metabolism in NIDDM.
Borkman M; Chisholm DJ; Furler SM; Storlien LH; Kraegen EW; Simons LA; Chesterman CN
Diabetes; 1989 Oct; 38(10):1314-9. PubMed ID: 2676659
[TBL] [Abstract][Full Text] [Related]
13. Fibrinolytic function after dietary supplementation with omega3 polyunsaturated fatty acids.
Toft I; Bønaa KH; Ingebretsen OC; Nordøy A; Jenssen T
Arterioscler Thromb Vasc Biol; 1997 May; 17(5):814-9. PubMed ID: 9157942
[TBL] [Abstract][Full Text] [Related]
14. Effects of fish oil on some parameters of fibrinolysis and lipoprotein(a) in healthy subjects.
Haglund O; Mehta JL; Saldeen T
Am J Cardiol; 1994 Jul; 74(2):189-92. PubMed ID: 8023790
[No Abstract] [Full Text] [Related]
15. Metabolic response to omega-3 fatty acid supplementation in patients with diabetic nephropathy: A randomized, double-blind, placebo-controlled trial.
Soleimani A; Taghizadeh M; Bahmani F; Badroj N; Asemi Z
Clin Nutr; 2017 Feb; 36(1):79-84. PubMed ID: 26611718
[TBL] [Abstract][Full Text] [Related]
16. Treatment for 2 mo with n 3 polyunsaturated fatty acids reduces adiposity and some atherogenic factors but does not improve insulin sensitivity in women with type 2 diabetes: a randomized controlled study.
Kabir M; Skurnik G; Naour N; Pechtner V; Meugnier E; Rome S; Quignard-Boulangé A; Vidal H; Slama G; Clément K; Guerre-Millo M; Rizkalla SW
Am J Clin Nutr; 2007 Dec; 86(6):1670-9. PubMed ID: 18065585
[TBL] [Abstract][Full Text] [Related]
17. Effects of fish oil supplementation on non-steroidal anti-inflammatory drug requirement in patients with mild rheumatoid arthritis--a double-blind placebo controlled study.
Lau CS; Morley KD; Belch JJ
Br J Rheumatol; 1993 Nov; 32(11):982-9. PubMed ID: 8220938
[TBL] [Abstract][Full Text] [Related]
18. Effect of omega 3 fatty acid on plasma lipids, cholesterol and lipoprotein fatty acid content in NIDDM patients.
Goh YK; Jumpsen JA; Ryan EA; Clandinin MT
Diabetologia; 1997 Jan; 40(1):45-52. PubMed ID: 9028717
[TBL] [Abstract][Full Text] [Related]
19. Treatment for 6 months with fish oil-derived n-3 polyunsaturated fatty acids has neutral effects on glycemic control but improves dyslipidemia in type 2 diabetic patients with abdominal obesity: a randomized, double-blind, placebo-controlled trial.
Wang F; Wang Y; Zhu Y; Liu X; Xia H; Yang X; Sun G
Eur J Nutr; 2017 Oct; 56(7):2415-2422. PubMed ID: 27913872
[TBL] [Abstract][Full Text] [Related]
20. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects.
Kruszynska YT; Yu JG; Olefsky JM; Sobel BE
Diabetes; 2000 Apr; 49(4):633-9. PubMed ID: 10871202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
